Retinoic acid postconsolidation therapy for high‐risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Retinoic Acid Postconsolidation Therapy for High‐risk Neuroblastoma Patients Treated With Autologous Haematopoietic Stem Cell Transplantation." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/439727/1/images/google-play-badge.png. Accessed 03 May 2024.
Retinoic acid postconsolidation therapy for high‐risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/439727/1/images/google-play-badge.png. Accessed May 3, 2024.
Retinoic acid postconsolidation therapy for high‐risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/439727/1/images/google-play-badge.png
Retinoic Acid Postconsolidation Therapy for High‐risk Neuroblastoma Patients Treated With Autologous Haematopoietic Stem Cell Transplantation [Internet]. In: Cochrane Abstracts. [cited 2024 May 03]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/439727/1/images/google-play-badge.png.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Retinoic acid postconsolidation therapy for high‐risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation
ID - 439727
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/439727/1/images/google-play-badge.png
DB - Evidence Central
DP - Unbound Medicine
ER -